Class information for:
Level 1: ALEMTUZUMAB//DACLIZUMAB//MS CLIN CENT TEXAS

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
22413 382 37.6 80%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
207 3       MULTIPLE SCLEROSIS//MYASTHENIA GRAVIS//MULTIPLE SCLEROSIS JOURNAL 52279
58 2             MULTIPLE SCLEROSIS//MULTIPLE SCLEROSIS JOURNAL//NEUROMYELITIS OPTICA 29459
22413 1                   ALEMTUZUMAB//DACLIZUMAB//MS CLIN CENT TEXAS 382

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ALEMTUZUMAB authKW 423337 15% 9% 56
2 DACLIZUMAB authKW 414922 8% 18% 29
3 MS CLIN CENT TEXAS address 213157 1% 67% 4
4 GENOME DISCOVERY UNITGENOME BIOL address 159869 1% 100% 2
5 AUTOIMMUNE TAUTOLOGY authKW 143880 1% 60% 3
6 NEUROIMMUNOL DIS UNIT address 133218 1% 33% 5
7 MULTIPLE SCLEROSIS authKW 125451 47% 1% 180
8 CD52 authKW 109603 3% 11% 12
9 DANISH REGISTER MULTIPLE SCLEROSIS address 106578 1% 67% 2
10 IMMUNOGLOBULIN G THERAPEUTIC USE authKW 106578 1% 67% 2

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Clinical Neurology 4972 49% 0% 189
2 Neurosciences 489 23% 0% 86
3 Immunology 312 15% 0% 58
4 Medicine, General & Internal 76 8% 0% 31
5 Rheumatology 62 3% 0% 10
6 Pharmacology & Pharmacy 40 9% 0% 33
7 Psychiatry 23 4% 0% 15
8 Medicine, Research & Experimental 20 4% 0% 15
9 Allergy 12 1% 0% 4
10 Endocrinology & Metabolism 8 3% 0% 12

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 MS CLIN CENT TEXAS 213157 1% 67% 4
2 GENOME DISCOVERY UNITGENOME BIOL 159869 1% 100% 2
3 NEUROIMMUNOL DIS UNIT 133218 1% 33% 5
4 DANISH REGISTER MULTIPLE SCLEROSIS 106578 1% 67% 2
5 NEURORX 106578 1% 67% 2
6 ANALYT DEV QC 79935 0% 100% 1
7 AZIENDA OSPED S GIOVANNI BATTISTA CITTA TORINA 79935 0% 100% 1
8 BIOANA 79935 0% 100% 1
9 BIOMED HOSP 79935 0% 100% 1
10 CELLULAR IMMUNOTHER Y PHARMACEUT S 79935 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 MULTIPLE SCLEROSIS JOURNAL 18048 6% 1% 23
2 ACTA NEUROLOGICA SCANDINAVICA 3359 4% 0% 16
3 MULTIPLE SCLEROSIS 2284 1% 1% 4
4 THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS 2086 1% 1% 2
5 MULTIPLE SCLEROSIS AND RELATED DISORDERS 1938 1% 1% 3
6 JOURNAL OF NEUROLOGY 1881 3% 0% 12
7 NEUROLOGY 1803 6% 0% 22
8 LANCET NEUROLOGY 1571 1% 0% 5
9 NEUROTHERAPEUTICS 1052 1% 0% 3
10 JOURNAL OF THE NEUROLOGICAL SCIENCES 943 3% 0% 11

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 ALEMTUZUMAB 423337 15% 9% 56 Search ALEMTUZUMAB Search ALEMTUZUMAB
2 DACLIZUMAB 414922 8% 18% 29 Search DACLIZUMAB Search DACLIZUMAB
3 AUTOIMMUNE TAUTOLOGY 143880 1% 60% 3 Search AUTOIMMUNE+TAUTOLOGY Search AUTOIMMUNE+TAUTOLOGY
4 MULTIPLE SCLEROSIS 125451 47% 1% 180 Search MULTIPLE+SCLEROSIS Search MULTIPLE+SCLEROSIS
5 CD52 109603 3% 11% 12 Search CD52 Search CD52
6 IMMUNOGLOBULIN G THERAPEUTIC USE 106578 1% 67% 2 Search IMMUNOGLOBULIN+G+THERAPEUTIC+USE Search IMMUNOGLOBULIN+G+THERAPEUTIC+USE
7 POLYAUTOIMMUNITY 105170 1% 26% 5 Search POLYAUTOIMMUNITY Search POLYAUTOIMMUNITY
8 OCRELIZUMAB 99911 1% 25% 5 Search OCRELIZUMAB Search OCRELIZUMAB
9 FAMILIAL AUTOIMMUNITY 89923 1% 38% 3 Search FAMILIAL+AUTOIMMUNITY Search FAMILIAL+AUTOIMMUNITY
10 ANTI CD52 MAB 79935 0% 100% 1 Search ANTI+CD52+MAB Search ANTI+CD52+MAB

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 WILLIS, MD , ROBERTSON, NP , (2016) ALEMTUZUMAB FOR MULTIPLE SCLEROSIS.CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS. VOL. 16. ISSUE 9. P. - 41 82% 0
2 WILLIS, MD , ROBERTSON, NP , (2015) ALEMTUZUMAB FOR THE TREATMENT OF MULTIPLE SCLEROSIS.THERAPEUTICS AND CLINICAL RISK MANAGEMENT. VOL. 11. ISSUE . P. 525 -534 36 77% 4
3 WILLIS, M , ROBERTSON, NP , (2014) DRUG SAFETY EVALUATION OF ALEMTUZUMAB FOR MULTIPLE SCLEROSIS.EXPERT OPINION ON DRUG SAFETY. VOL. 13. ISSUE 8. P. 1115 -1124 35 76% 1
4 WILLIS, MD , HARDING, KE , PICKERSGILL, TP , WARDLE, M , PEARSON, OR , SCOLDING, NJ , SMEE, J , ROBERTSON, NP , (2016) ALEMTUZUMAB FOR MULTIPLE SCLEROSIS: LONG TERM FOLLOW-UP IN A MULTI-CENTRE COHORT.MULTIPLE SCLEROSIS JOURNAL. VOL. 22. ISSUE 9. P. 1215 -1223 21 75% 4
5 RUCK, T , BITTNER, S , WIENDL, H , MEUTH, SG , (2015) ALEMTUZUMAB IN MULTIPLE SCLEROSIS: MECHANISM OF ACTION AND BEYOND.INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. VOL. 16. ISSUE 7. P. 16414 -16439 35 52% 6
6 COYLE, PK , (2014) CURRENT EVALUATION OF ALEMTUZUMAB IN MULTIPLE SCLEROSIS.EXPERT OPINION ON BIOLOGICAL THERAPY. VOL. 14. ISSUE 1. P. 127-135 23 85% 2
7 DOBSON, R , GIOVANNONI, G , (2013) AUTOIMMUNE DISEASE IN PEOPLE WITH MULTIPLE SCLEROSIS AND THEIR RELATIVES: A SYSTEMATIC REVIEW AND META-ANALYSIS.JOURNAL OF NEUROLOGY. VOL. 260. ISSUE 5. P. 1272-1285 28 64% 18
8 HARTUNG, HP , AKTAS, O , BOYKO, AN , (2015) ALEMTUZUMAB: A NEW THERAPY FOR ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS.MULTIPLE SCLEROSIS JOURNAL. VOL. 21. ISSUE 1. P. 22 -34 18 78% 14
9 MARRIE, RA , REIDER, N , COHEN, J , STUVE, O , SORENSEN, PS , CUTTER, G , REINGOLD, SC , TROJANO, M , (2015) A SYSTEMATIC REVIEW OF THE INCIDENCE AND PREVALENCE OF AUTOIMMUNE DISEASE IN MULTIPLE SCLEROSIS.MULTIPLE SCLEROSIS JOURNAL. VOL. 21. ISSUE 3. P. 282 -293 28 52% 10
10 BAGIR, LV , BATYSHEVA, TT , BOYKO, AN , GUSEV, YI , (2009) PATHOLOGY OF THE THYROID GLAND AND MULTIPLE SCLEROSIS: A POSSIBLE INFLUENCE ON EFFICACY AND TOLERABILITY OF TREATMENT.ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA. VOL. 109. ISSUE 1. P. 10-15 24 77% 1

Classes with closest relation at Level 1


Rank Class id link
1 1131 INTERFERON BETA//MULTIPLE SCLEROSIS//GLATIRAMER ACETATE
2 22994 DIMETHYL FUMARATE//FUMARIC ACID ESTERS//MONOMETHYL FUMARATE
3 26412 LINOMIDE//LAQUINIMOD//TASQUINIMOD
4 10206 INTERFERON ALPHA//INTERFERON//CHRONIC HEPATITIS C
5 10963 MYELIN OLIGODENDROCYTE GLYCOPROTEIN//MULTIPLE SCLEROSIS//NEUROIMMUNOL
6 27446 CLALIT HLTH SERV TEL AVIV//AUTOIMMUNE THYROID DISEASE//CHRONIC LYMPHOCYTIC THYROIDITIS
7 3080 MULTIPLE SCLEROSIS//MULTIPLE SCLEROSIS JOURNAL//NORWEGIAN MULTIPLE SCLEROSIS COMPETENCE
8 2902 PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY//JC VIRUS//NATALIZUMAB
9 8190 MULTIPLE SCLEROSIS//FAMILIAL MULTIPLE SCLEROSIS//PROGRAM NEUROPSYCHIAT GENOM
10 8195 BASILIXIMAB//THYMOGLOBULIN//DACLIZUMAB

Go to start page